高级检索
当前位置: 首页 > 详情页

Microglial hexokinase 2 deficiency increases ATP generation through lipid metabolism leading to β-amyloid clearance

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Xiamen Univ, Sch Med, Inst Neurosci, Fujian Prov Key Lab Neurodegenerat Dis & Aging Re, Xiamen, Peoples R China [2]Beijing Inst Basic Med Sci, Brain Sci Ctr, Beijing, Peoples R China [3]Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA [4]Xiamen Univ, Dept Anesthesiol, Affiliated Hosp 1, Xiamen, Fujian, Peoples R China [5]Fourth Mil Medcial Univ, Sch Basic Med, Dept Neurobiol, Xian, Shaanxi, Peoples R China [6]Capital Med Univ, Beijing Tongren Hosp, Beijing Tongren Eye Ctr, Beijing Ophthalmol & Visual Sci Key Lab,Beijing I, Beijing, Peoples R China [7]Chinese Univ Hong Kong, Sch Life Sci, Sha Tin, Hong Kong, Peoples R China [8]Fujian Med Univ, Inst Neurosci, Fuzhou, Peoples R China
出处:
ISSN:

摘要:
Microglial cells consume adenosine triphosphate (ATP) during phagocytosis to clear neurotoxic beta-amyloid in Alzheimer's disease (AD). However, the contribution of energy metabolism to microglial function in AD remains unclear. Here, we demonstrate that hexokinase 2 (HK2) is elevated in microglia from an AD mouse model (5xFAD) and AD patients. Genetic deletion or pharmacological inhibition of HK2 significantly promotes microglial phagocytosis, lowers the amyloid plaque burden and attenuates cognitive impairment in male AD mice. Notably, the ATP level is dramatically increased in HK2-deficient or inactive microglia, which can be attributed to a marked upregulation in lipoprotein lipase (LPL) expression and subsequent increase in lipid metabolism. We further show that two downstream metabolites of HK2, glucose-6-phosphate and fructose-6-phosphate, can reverse HK2-deficiency-induced upregulation of LPL, thus supporting ATP production and microglial phagocytosis. Our findings uncover a crucial role for HK2 in phagocytosis through regulation of microglial energy metabolism, suggesting a potential therapeutic strategy for AD by targeting HK2.

基金:

基金编号: 91849205 81925010 U1905207 81801337 82071520 92149303 92049202 2021YFA1101402 20720190118 20720180049 20720190075 2019J05006 3502Z20206031

语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2021]版:
大类 | 1 区 医学
小类 | 1 区 内分泌学与代谢
最新[2025]版:
大类 | 1 区 医学
小类 | 1 区 内分泌学与代谢
JCR分区:
出版当年[2020]版:
Q1 ENDOCRINOLOGY & METABOLISM
最新[2023]版:
Q1 ENDOCRINOLOGY & METABOLISM

影响因子: 最新[2023版] 最新五年平均 出版当年[2020版] 出版当年五年平均 出版前一年[2019版] 出版后一年[2021版]

第一作者:
第一作者机构: [1]Xiamen Univ, Sch Med, Inst Neurosci, Fujian Prov Key Lab Neurodegenerat Dis & Aging Re, Xiamen, Peoples R China
通讯作者:
通讯机构: [1]Xiamen Univ, Sch Med, Inst Neurosci, Fujian Prov Key Lab Neurodegenerat Dis & Aging Re, Xiamen, Peoples R China [4]Xiamen Univ, Dept Anesthesiol, Affiliated Hosp 1, Xiamen, Fujian, Peoples R China [8]Fujian Med Univ, Inst Neurosci, Fuzhou, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:25471 今日访问量:0 总访问量:1498 更新日期:2025-06-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学附属北京同仁医院 技术支持:重庆聚合科技有限公司 地址:北京市东城区东交民巷1号(100730)